Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

king it available in 30 countries across Europe. - Shire has seen rapid adoption of VPRIV worldwide. There are currently over 1,000 Gaucher patients treated with VPRIV and initiation of treatment continues. Based on its current manufacturing capacity, Shire anticipates being able to accommodate approximately 200 additional Gaucher patients until the approval of the Lexington Manufacturing facility provides substantial additional capacity. Shire has an ongoing program to monitor demand and manage requests for VPRIV. Shire's priority is ensuring long-term, uninterrupted treatment of patients on therapy. FIRAZYR - for the treatment of HAE - In October 2010, Shire submitted data to support a change in the label in the EU to include the potential for self-administered subcutaneous injections of FIRAZYR in patients who are experiencing acute attacks of HAE.

Pipeline

This quarter we have made significant developments in our pipeline, including:

Collaboration with Acceleron for ActRIIB molecules - On September 9, 2010 Shire announced the expansion of its HGT pipeline through the exclusive licence, in markets outside of North America, for the ActRIIB class of molecules being developed by Acceleron. The collaboration will initially investigate ACE-031, Acceleron's lead ActRIIB drug candidate, which is currently in a Phase 2a trial for the treatment of patients with Duchenne Muscular Dystrophy. ACE-031 and other ActRIIB molecules have the potential to be used in other muscular and neuromuscular disorders with high unmet medical need. Pipeline obtained through Movetis acquisition - The acquisition of Movetis brings to Shire a promising GI pipeline, offering additional opportunities that include two projects in early clinical development and several pre-clinical leads as well as the rights to a large library of qualified lead compounds with potential for development in different GI indications. VYVANSE for the adjunctive therapy in the treatment of ina
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders announced ... as Chief Operating Officer.  Reporting directly to ... Officer, Robert will oversee the planned global commercial ... for LAL Deficiency, and will have responsibility for ...
(Date:9/21/2014)... Chemical Sciences play a significant role in meeting ... safe water, healthy food, and dependable medicine from ... educators, and scientists have a great role in ... for the national development, and to foster research ... emerging Sciences, accelerating with a tremendous speed to ...
(Date:9/19/2014)... BRISBANE, Calif., Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... into a Memorandum of Understanding to settle the litigation ... Agreement and Plan of Merger dated as of August ... and InterMune, Inc.  As one term of the Memorandum ... disclosures set forth in the attached exhibit reflecting the ...
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , , Mark Churchill 1 , Mark Harrison 1 , , ... , 1 Thermo Finnigan, Stafford House, 1 Boundary Park, Boundary Way, ... Aker University Hospital, Hormone Laboratory, Section for Doping Analysis,Trondheimsveien, , N-0514, Oslo, Norway, ... , Monitoring Clenbuterol in Humans , , , ...
... , , , , , , , ... , Features and benefits , , , , , ... transfection of siRNA for effective gene silencing , Quick and easy setup ... for absence of RNase activity , , , , , ...
... , , , , QIAshredder spin columns are designed for simple and rapid ... , , , , ... , , , ... tissue lysates, , plant cell or tissue lysates, white blood cell lysates, ...
Cached Biology Technology:Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 2Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 3Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 4Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 5TransMessenger Transfection Reagent 2TransMessenger Transfection Reagent 3QIAshredder Homogenizer 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... The sense of fairness did not evolve for the ... reap the benefits of continued cooperation, so say Frans ... a review article about inequity aversion (IA), which is ... review is published in Science . , ... 35 IA-related studies to address their hypothesis that it ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... When researchers sequence the RNA of cancer cells, they can ... RNA. That can help lead them to the gene or protein ... a few known instigators, what does it mean? Is there more ... fast enough? What part of the biological equilibrium is off? ...
... the first time that primates modify their body movements to ... Humans unconsciously modify their movements to be in synchrony with ... in step or clap in unison at the end of ... facilitate human interaction. Researchers from the RIKEN Brain Science Institute ...
... patients with an inherited heart condition known as arrhythmogenic ... problem until they,re in their early 20s. The lack ... for researchers to study how ARVD/C evolves or to ... 2012 Nobel Prize winner Shinya Yamanaka, M.D., Ph.D., helps ...
Cached Biology News:New technique sheds light on RNA 2Primates too can move in unison 2Patients' own skin cells are transformed into heart cells to create 'disease in a dish' 2Patients' own skin cells are transformed into heart cells to create 'disease in a dish' 3
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... variant: With the macro- and ... and Skoog (1962) and the ... et al. (1968). Preparation Quantity ... grams of powder per liter ...
... CBED Maxi Kit provides a fast and ... protein solutions for buffer exchange, and for removing ... kit is based on spin-column chromatography using Norgens ... such as MgCl 2 , NaCl, KCl, CaCl ...
Biology Products: